Novo Nordisk NVO has experienced remarkable growth in recent years, largely fueled by the commercial success of its blockbuster semaglutide (GLP-1 RA)-based therapies, Wegovy for obesity and ...

If you're looking for a top healthcare stock to buy that has much more upside in GLP-1, then going with Eli Lilly or Novo Nordisk can make much more sense at this stage.

Amgen recently released the full data from a trial involving its GLP-1 drug, MariTide. More than one-quarter of the participants on the highest dosage of the drug had to stop taking it due to ...

Novo Nordisk has asked the FDA to block compounders from making versions of its older, once-daily GLP-1 agonist liraglutide.

Novo Nordisk has abandoned a kidney disease drug it licensed from KBP Biosciences last year in a deal valued at up to $1.3bn.

FDA erteilt De-Novo-Zulassung für das Spur® Peripheral Retrievable Stent System von Reflow Medical ...

Jared Holz, Mizuho Securities health care strategist, joins CNBC's 'Squawk on the Street' to discuss weight loss drug makers, how CVS is boosting access to Wegovy, and more.

Il sagit d’une solution clinique unique pour le traitement des lésions De Novo ou resténotiques après prédilatation chez les patients atteints d'une maladie artérielle infrapoplitée.

Po krótkiej przerwie technicznej jedna z najbardziej rozpoznawalnych atrakcji Krakowa — ziejący ogniem Smok Wawelski — znów cieszy oczy mieszkańców i turystów. W poniedziałek, 14 lipca ...

COPENHAGEN (dpa-AFX) - Novo Nordisk A/S (NVO) released a profit for its first quarter that increased from the same period last yearThe company's earnings totaled DKK29.034 billion, or DKK6.53 per ...

View the latest Walmart Inc. (WMT) stock price, news, historical charts, analyst ratings and financial information from WSJ.